{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:19:11Z","timestamp":1791458351717,"version":"4.3.4"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Testicular germ cell tumors (TGCT) are highly curable malignancies, with excellent survival rates largely attributable to advances in cancer treatment. Consequently, there is a growing population of long-term TGCT survivors whose life expectancy approaches that of the general population. However, these survivors may experience acute and late adverse effects of cancer treatment, with cardiovascular toxicity being among the most serious and potentially life-threatening.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This narrative review synthesizes current evidence on cardiovascular toxicity in testicular cancer survivors, including clinical manifestations, pathophysiology of cisplatin-induced cardiovascular damage, additional adverse effects of radiotherapy, and prevalence of traditional cardiovascular risk factors. Key clinical guidelines, observational studies, and experimental findings were analyzed to identify trends, knowledge gaps, and opportunities for improving survivorship care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Multiple studies consistently demonstrate an increased risk of cardiovascular disease (CVD) among TGCT survivors, particularly following cisplatin-based chemotherapy. Common clinical manifestations include myocardial infarction, angina pectoris, cerebrovascular events, thromboembolism, and heart failure. The highest risk occurs within the first year post-treatment but may persist or recur even after a decade. Cisplatin-induced cardiovascular toxicity involves vascular injury - characterized by endothelial dysfunction, oxidative stress, and prothrombotic state - and myocardial damage driven by oxidative stress, inflammation, and apoptosis. Furthermore, TGCT survivors exhibit a higher prevalence of traditional cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, diabetes, and obesity, contributing to the overall elevated CVD risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>There is an urgent need for a structured, long-term survivorship care model for TGCT survivors. Cardiovascular risk assessment and prevention should be central components, especially in survivors treated with cisplatin-based chemotherapy. Early detection of treatment-related toxicities, combined with lifestyle interventions and regular monitoring, is essential. Future research should focus on elucidating molecular mechanisms of cardiovascular toxicity, validating TGCT survivor-specific screening tools, identifying early biomarkers of cardiac injury, and exploring pharmacologic and behavioral interventions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Protecting cardiovascular health in TGCT survivors requires a proactive, personalized, and multidisciplinary approach. Integrating cardiometabolic monitoring, risk factor modification, and tailored follow-up strategies into survivorship care is vital. Focused research and clinical attention are needed to ensure that the long-term success of cancer treatment is not compromised by preventable cardiovascular disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1654063","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:16:07Z","timestamp":1755058567000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular toxicity in testicular germ cell tumor survivors"],"prefix":"10.3389","volume":"15","author":[{"given":"Zuzana","family":"Orszaghova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Mladosievicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Chovanec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","article-title":"Causes of death \u2013 deaths by country of residence and occurrence (dataset?code: hlth_cd_aro)","year":"2023"},{"key":"B2","volume-title":"Mortality in the United States, 2022","author":"Kochanek","year":"2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01017-x","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32810","article-title":"Testicular cancer incidence predictions in Europe 2010-2035: A rising burden despite population ageing","volume":"147","author":"Znaor","year":"2020","journal-title":"Int J Cancer"},{"key":"B5","volume-title":"SEER Cancer Stat Facts: Testicular Cancer","year":"2025"},{"key":"B6","article-title":"Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture","volume":"41","author":"Einhorn","year":"1981","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium","volume":"39","author":"Gillessen","year":"2021","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03292","article-title":"Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium","volume":"39","author":"Beyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv131","article-title":"Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data","volume":"26","author":"Capocaccia","year":"2015","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00440-w","article-title":"Late adverse effects and quality of life in survivors of testicular germ cell tumour","volume":"18","author":"Chovanec","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"108116","DOI":"10.1016\/j.pharmthera.2022.108116","article-title":"Endothelial dysfunction as a complication of anti-cancer therapy","volume":"237","author":"Terwoord","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"10760296211024756","DOI":"10.1177\/10760296211024756","article-title":"Predictors of venous thromboembolism in patients with testicular germ cell tumors: A retrospective study","volume":"27","author":"Abdel-Razeq","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2598-7","article-title":"Predictors of thrombosis in testicular cancer during platinum-based chemotherapy","volume":"37","author":"Paffenholz","year":"2019","journal-title":"World J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i3.183","article-title":"Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy","volume":"12","author":"Shields","year":"2021","journal-title":"World J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-10420-w","article-title":"Long-term cardiotoxicity in germ cell cancer survivors after platinum-based chemotherapy: cardiac MR shows impaired systolic function and tissue alterations","volume":"34","author":"Beitzen-Heineke","year":"2024","journal-title":"Eur Radiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01180","article-title":"Cardiovascular risk factors and disease after male germ cell cancer","volume":"38","author":"Lauritsen","year":"2020","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Bjerring","year":"2000","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.173","article-title":"Cardiovascular disease as a long-term complication of treatment for testicular cancer","volume":"21","author":"Meinardi","year":"2003","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7193","article-title":"Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer","volume":"24","author":"Ozben","year":"2006","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second Malignancies and cardiovascular disease in 5-year survivors of testicular cancer","volume":"25","author":"El-Awady el","year":"2007","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Dieckmann","year":"2010","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3654","article-title":"Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: A population-based study","volume":"33","author":"Huddart","year":"2015","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0735","article-title":"Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: A multi-institutional study","volume":"36","author":"van den Belt-Dusebout","year":"2018","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01016","article-title":"Cardiovascular disease in testicular cancer survivors: identification of risk factors and impact on quality of life","volume":"41","author":"van den Belt-Dusebout","year":"2023","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28086","article-title":"Outcomes in stage I testicular seminoma: a population-based study of 9193 patients","volume":"119","author":"Haugnes","year":"2013","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaa289","article-title":"The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up","volume":"22","author":"Fung","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/1076029607303334","article-title":"Acute anterior myocardial infarction after chemotherapy for testicular seminoma in a young patient","volume":"13","author":"Kerns","year":"2007","journal-title":"Clin Appl Thromb Hemost"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies","volume":"650","author":"Lubberts","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1159\/000512055","article-title":"Thromboembolic events in patients with testicular germ cell tumours are predominantly triggered by advanced disease and by central venous access systems","volume":"5","author":"Beard","year":"2021","journal-title":"Urol Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40959-021-00120-z","article-title":"Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms","volume":"7","author":"Clasen","year":"2021","journal-title":"Cardiooncology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01049-3","article-title":"Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy","volume":"123","author":"Stelwagen","year":"2020","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.037","article-title":"Early breast cancer therapy and cardiovascular injury","volume":"50","author":"Jones","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0051","article-title":"Late cardiovascular toxicity following chemotherapy for germ cell tumors","volume":"10","author":"Feldman","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq216","article-title":"Testicular cancer survivorship: research strategies and recommendations","volume":"102","author":"Travis","year":"2010","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B37","article-title":"Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour","volume":"31","author":"Dieckmann","year":"2011","journal-title":"Anticancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23389","article-title":"Cardiovascular risk in long-term survivors of testicular cancer","volume":"112","author":"Vaughn","year":"2008","journal-title":"Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"Gietema","year":"2000","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.3046","article-title":"Single cell sequencing unveils endothelial alterations after cisplatin treatment","volume":"43","author":"Pan","year":"2022","journal-title":"Eur Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ajpath.2023.09.012","article-title":"The role of endothelial cells in atherosclerosis: insights from genetic association studies","volume":"194","author":"Pepin","year":"2024","journal-title":"Am J Pathol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12872-015-0124-z","article-title":"Endothelial cell control of thrombosis","volume":"15","author":"Yau","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S385772","article-title":"Thrombotic pathogenesis and laboratory diagnosis in cancer patients, an update","volume":"16","author":"Akinbo","year":"2023","journal-title":"Int J Gen Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1372817","article-title":"Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells","volume":"11","author":"Koukorava","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00260.x","article-title":"Von Willebrand factor, platelets and endothelial cell interactions","volume":"1","author":"Ruggeri","year":"2003","journal-title":"J Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2169","article-title":"Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature","volume":"18","author":"Weijl","year":"2000","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.06.004","article-title":"Comprehensive characterization of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer","volume":"2","author":"Cameron","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.4092","article-title":"Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12967-018-1471-1","article-title":"Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway","volume":"16","author":"Achkar","year":"2018","journal-title":"J Transl Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cbi.2013.11.008","article-title":"Exploring the protective role of apocynin, a specific NADPH oxidase inhibitor, in cisplatin-induced cardiotoxicity in rats","volume":"207","author":"El-Sawalhi","year":"2014","journal-title":"Chem Biol Interact"},{"key":"B51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","article-title":"An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures","volume":"371","author":"Dugbartey","year":"2016","journal-title":"Toxicology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14740338.2020.1700228","article-title":"Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia","volume":"19","author":"Chrysant","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf058","article-title":"Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer","volume":"13","author":"Strumberg","year":"2002","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.12.012","article-title":"Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer","volume":"40","author":"Nuver","year":"2004","journal-title":"Eur J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.176","article-title":"The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl372","article-title":"Components of the metabolic syndrome in long-term survivors of testicular cancer","volume":"18","author":"Haugnes","year":"2007","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.226","article-title":"Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors","volume":"109","author":"Willemse","year":"2013","journal-title":"Br J Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.05.022","article-title":"Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy","volume":"63","author":"Lubberts","year":"2016","journal-title":"Eur J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12354","article-title":"Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome","volume":"5","author":"Bogefors","year":"2017","journal-title":"Andrology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.01.011","article-title":"Predicting cardiovascular disease among testicular cancer survivors after modern cisplatin-based chemotherapy: application of the framingham risk score","volume":"16","author":"Feldman","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"B62","volume-title":"The Health Consequences of Smoking\u201450 Years of Progress: A Report of the Surgeon General","year":"2014"},{"key":"B63","volume-title":"Cancer Trends Progress Report. U.S. Department of Health and Human Services, National Institutes of Health","year":"2025"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.07.024","article-title":"Smoking and disease outcomes in patients with Malignant germ cell tumors","author":"O'Donnell","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad039","article-title":"Smoking as a prognostic factor for survival in patients with disseminated germ cell cancer","volume":"115","author":"Bandak","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"B66","unstructured":"Dyslipidemias - meSH\n          \n          2025"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e17017","DOI":"10.1200\/JCO.2025.43.16_suppl.e17017","article-title":"Dyslipidemia in long-term survivors of testicular germ cell tumors","volume":"43","author":"Orszaghova","year":"2025","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90911-U","article-title":"Abdominal radiotherapy is a cause for chronic pancreatitis","volume":"105","author":"Levy","year":"1993","journal-title":"Gastroenterology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0248-x","article-title":"Risk of diabetes after para-aortic radiation for testicular cancer","volume":"119","author":"Groot","year":"2018","journal-title":"Br J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwac187","article-title":"Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation","volume":"29","author":"Lopez-Jimenez","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac030","article-title":"Associations of body fat distribution and cardiometabolic risk of testicular cancer survivors after cisplatin-based chemotherapy","volume":"6","author":"Wibmer","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.4.683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome","volume":"24","author":"Isomaa","year":"2001","journal-title":"Diabetes Care"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.21.2709","article-title":"The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men","volume":"288","author":"Lakka","year":"2002","journal-title":"JAMA"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0372","article-title":"Obesity, metabolic syndrome, and cardiovascular disease","volume":"89","author":"Grundy","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome\u2013a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds527","article-title":"Early development of the metabolic syndrome after chemotherapy for testicular cancer","volume":"24","author":"de Haas","year":"2013","journal-title":"Ann Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11764-007-0012-3","article-title":"Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer","volume":"1","author":"Wethal","year":"2007","journal-title":"J Cancer Surviv"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.7046","article-title":"Clinical and genetic risk factors for adverse metabolic outcomes in north american testicular cancer survivors","volume":"16","author":"Zaid","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet1050","article-title":"Testosterone and ill-health in aging men","volume":"5","author":"Yeap","year":"2009","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-015-9323-2","article-title":"The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease","volume":"16","author":"Traish","year":"2015","journal-title":"Rev Endocr Metab Disord"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12177","article-title":"Testosterone deficiency in testicular cancer survivors - a systematic review and meta-analysis","volume":"4","author":"Bandak","year":"2016","journal-title":"Andrology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.12.010","article-title":"Biochemical hypogonadism in aging testicular cancer survivors: A clinical challenge","volume":"72","author":"Fossa","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7109","article-title":"Adverse health outcomes in relationship to hypogonadism after chemotherapy: A multicenter study of testicular cancer survivors","volume":"17","author":"Abu Zaid","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e472654","DOI":"10.1200\/EDBK-25-472654","article-title":"Key updates in testicular cancer: optimizing survivorship and survival","volume":"45","author":"Bagrodia","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B85","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","article-title":"Cardiovascular considerations after cancer therapy: gaps in evidence and JACC: cardioOncology expert panel recommendations","volume":"7","author":"Blaes","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.06.007","article-title":"How to manage cisplatin-based chemotherapy-related cardiovascular disease in patients with testicular cancer","volume":"4","author":"Kadambi","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B89","doi-asserted-by":"publisher","first-page":"17562872251322658","DOI":"10.1177\/17562872251322658","article-title":"Physical activity and testicular cancer survivorship health-related quality of life: a scoping review","volume":"17","author":"Rovito","year":"2025","journal-title":"Ther Adv Urol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00520-023-08000-1","article-title":"Habitual physical activity modulates cardiometabolic health in long-term testicular cancer survivors","volume":"31","author":"Amiri","year":"2023","journal-title":"Support Care Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13078","article-title":"Chemotherapy-induced toxicity in patients with testicular germ cell tumors: The impact of physical fitness and regular exercise","volume":"9","author":"Amiri","year":"2021","journal-title":"Andrology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34625","article-title":"Association of physical activity with overall mortality among long-term testicular cancer survivors: A longitudinal study","volume":"153","author":"Thorsen","year":"2023","journal-title":"Int J Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30859","article-title":"Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial","volume":"123","author":"Adams","year":"2017","journal-title":"Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.995776","article-title":"Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship","volume":"54","author":"Christensen","year":"2015","journal-title":"Acta Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000002117","article-title":"American college of sports medicine roundtable report on physical activity, sedentary behavior, and cancer prevention and control","volume":"51","author":"Patel","year":"2019","journal-title":"Med Sci Sports Exerc"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.09.013","article-title":"Changes in physical activity and cardiovascular disease risk in cancer survivors: A nationwide cohort study","volume":"6","author":"Jung","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0028","article-title":"NCCN guidelines\u00ae Insights: survivorship, version 2.2025: featured updates to the NCCN guidelines\u00ae","volume":"23","author":"Sanft","year":"2025","journal-title":"J Natl Compr Cancer Netw"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1654063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:16:14Z","timestamp":1755058574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1654063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":97,"alternative-id":["10.3389\/fonc.2025.1654063"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1654063","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1654063"}}